Table 1.
Baseline characteristics of the participants.
| P value | |||||
|---|---|---|---|---|---|
| NAFLD (n = 50) | CHB (n = 31) | CHB and NAFLD (n = 51) | NAFLD vs. CHB | NAFLD vs. CHB and NAFLD | |
| Gender (female/male) | 13/37 | 8/23 | 8/43 | 0.985 | 0.202 |
| Age | 37.72 ± 10.49 | 38.90 ± 7.49 | 41.29 ± 10.46 | 0.363 | 0.115 |
| BMI | 27.99 ± 3.19 | 21.58 ± 2.38 | 25.62 ± 3.45 | <0.0001 | <0.0001 |
| ALT | 117.78 ± 84.17 | 68.35 ± 68.01 | 62.25 ± 50.80 | <0.0001 | <0.0001 |
| AST | 56.20 ± 31.81 | 42.32 ± 36.26 | 35.80 ± 20.15 | 0.001 | <0.0001 |
| HBeAg-positive rate | / | 15/31 | 19/51 | 0.321 | / |
| Hypertension | 7/50 | / | 9/51 | / | 0.616 |
| Diabetes | 6/50 | / | 6/51 | / | 0.971 |
| Hyperlipidemia | 46/50 | / | 24/51 | / | <0.0001 |
| Steatosis | / | <0.0001 | |||
| S1 | 17/50 | / | 37/51 | ||
| S2 | 27/50 | / | 13/51 | ||
| S3 | 6/50 | / | 1/51 | ||
NAFLD: nonalcoholic fatty liver disease; CHB: chronic hepatitis B; BMI: body mass index; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HBeAg: HBV e antigen.